Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Phase I Study to evaluate safety and tolerability of PRO-230 (atropine sulphate 0.05%)
ophthalmic solution through evaluation of incidence of non-expected adverse events (AE),
photophobia, pupillary diameter, incidence of expected adverse events, and best near
corrected visual acuity (BNCVA)